JW Pharmaceutical Successfully Holds Symposium to Mark 7th Anniversary of Hemlibra Approval in Korea
Sharing Long-term Safety and Real-world Data
JW Pharmaceutical announced on the 24th that it held the "HAVEN-SEVEN Symposium" on the 13th at the Westin Chosun Parnas in Gangnam-gu, Seoul, to commemorate the 7th anniversary of the domestic approval of Hemlibra (active ingredient emicizumab), a treatment for hemophilia A.
This symposium was organized to share long-term safety data and accumulated real-world data (RWD) on Hemlibra with domestic medical professionals specializing in hemophilia treatment.
JW Pharmaceutical held the 'HAVEN-SEVEN Symposium' on the 13th at The Westin Chosun Parnas in Gangnam-gu, Seoul, to commemorate the 7th anniversary of the domestic approval of Hemlibra (active ingredient emicizumab), a treatment for hemophilia A. JW Pharmaceutical
View original imageProfessor Park Youngsil of the Department of Pediatrics at Kyung Hee University Hospital at Gangdong, who served as a speaker, gave a presentation on "Evidence of Safety Confirmed by Global Data and Domestic RWD." Introducing data from more than 24,000 patients accumulated over 10 years since the global launch, she stated, "Despite the increase in the number of patients, the incidence rate of severe thromboembolic events remained low, at 0.17 cases per 100 patient-years of observation."
She continued, "There was one newly reported case of thrombotic microangiopathy (TMA), which occurred under conditions of high-dose bypassing agent (aPCC) combination exceeding guideline recommendations, and no associated risk was observed with Hemlibra monotherapy. Long-term safety profiles were further confirmed through RWD from the UK, the US, Europe, as well as data on special patient groups such as the elderly and infants."
Professor Han Jungwoo of the Department of Pediatrics at Severance Hospital, Yonsei University, stated, "Recently, the goals of hemophilia treatment have expanded beyond bleeding prevention to improving physical activity and quality of life. In a study tracking 112 patients with hemophilia A who exercised regularly over 12 months, neither exercise frequency nor participation in high-risk sports directly increased the risk of bleeding, and after switching to Hemlibra, only 0.2% of all exercise sessions were associated with bleeding incidents."
Professor Baek Heejo of the Department of Pediatrics at Chonnam National University Hwasun Hospital emphasized, "In a treatment environment with reduced annual bleeding rates (ABR), a 'floor effect' may occur, making it difficult to fully assess patient conditions using only the ABR indicator. Therefore, complementary indices such as joint health, patient-reported outcomes, and treatment burden should also be considered."
JW Pharmaceutical plans to continue sharing treatment strategies based on long-term safety and real-world data on Hemlibra according to the life cycle. Through this, the company aims to contribute to establishing a patient-centered treatment environment that considers not only bleeding prevention but also physical activity, joint health, and improvement in quality of life.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A JW Pharmaceutical representative stated, "This symposium was an opportunity to share the long-term safety and clinical value of Hemlibra, as confirmed in real-world clinical settings, with domestic medical professionals. We will continue academic exchanges with healthcare professionals to help patients with hemophilia maintain their daily lives in a more stable treatment environment."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.